Predictive algorithms developed using APOE genotyping, tau-PET imaging, and plasma neurofilament light chain (NfL) levels are leading to earlier diagnoses of neurodegenerative diseases and further enhancing the application of targeted therapies. This evidence concerns the gene NEFL and neurodegenerative disease.